Monoclonal antibodies and toxins--a perspective on function and isotype.

Siu Kei Chow, Arturo Casadevall

Research output: Contribution to journalArticle

Abstract

Antibody therapy remains the only effective treatment for toxin-mediated diseases. The development of hybridoma technology has allowed the isolation of monoclonal antibodies (mAbs) with high specificity and defined properties, and numerous mAbs have been purified and characterized for their protective efficacy against different toxins. This review summarizes the mAb studies for 6 toxins--Shiga toxin, pertussis toxin, anthrax toxin, ricin toxin, botulinum toxin, and Staphylococcal enterotoxin B (SEB)--and analyzes the prevalence of mAb functions and their isotypes. Here we show that most toxin-binding mAbs resulted from immunization are non-protective and that mAbs with potential therapeutic use are preferably characterized. Various common practices and caveats of protection studies are discussed, with the goal of providing insights for the design of future research on antibody-toxin interactions.

Original languageEnglish (US)
Pages (from-to)430-454
Number of pages25
JournalToxins
Volume4
Issue number6
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Shiga Toxin
Immunization
Ricin
Botulinum Toxins
Antibodies
Pertussis Toxin
Hybridomas
Therapeutic Uses
Technology
Therapeutics

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Monoclonal antibodies and toxins--a perspective on function and isotype. / Chow, Siu Kei; Casadevall, Arturo.

In: Toxins, Vol. 4, No. 6, 06.2012, p. 430-454.

Research output: Contribution to journalArticle

@article{3e5f86e65d404f5180b27f319bf19931,
title = "Monoclonal antibodies and toxins--a perspective on function and isotype.",
abstract = "Antibody therapy remains the only effective treatment for toxin-mediated diseases. The development of hybridoma technology has allowed the isolation of monoclonal antibodies (mAbs) with high specificity and defined properties, and numerous mAbs have been purified and characterized for their protective efficacy against different toxins. This review summarizes the mAb studies for 6 toxins--Shiga toxin, pertussis toxin, anthrax toxin, ricin toxin, botulinum toxin, and Staphylococcal enterotoxin B (SEB)--and analyzes the prevalence of mAb functions and their isotypes. Here we show that most toxin-binding mAbs resulted from immunization are non-protective and that mAbs with potential therapeutic use are preferably characterized. Various common practices and caveats of protection studies are discussed, with the goal of providing insights for the design of future research on antibody-toxin interactions.",
author = "Chow, {Siu Kei} and Arturo Casadevall",
year = "2012",
month = "6",
language = "English (US)",
volume = "4",
pages = "430--454",
journal = "Toxins",
issn = "2072-6651",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - Monoclonal antibodies and toxins--a perspective on function and isotype.

AU - Chow, Siu Kei

AU - Casadevall, Arturo

PY - 2012/6

Y1 - 2012/6

N2 - Antibody therapy remains the only effective treatment for toxin-mediated diseases. The development of hybridoma technology has allowed the isolation of monoclonal antibodies (mAbs) with high specificity and defined properties, and numerous mAbs have been purified and characterized for their protective efficacy against different toxins. This review summarizes the mAb studies for 6 toxins--Shiga toxin, pertussis toxin, anthrax toxin, ricin toxin, botulinum toxin, and Staphylococcal enterotoxin B (SEB)--and analyzes the prevalence of mAb functions and their isotypes. Here we show that most toxin-binding mAbs resulted from immunization are non-protective and that mAbs with potential therapeutic use are preferably characterized. Various common practices and caveats of protection studies are discussed, with the goal of providing insights for the design of future research on antibody-toxin interactions.

AB - Antibody therapy remains the only effective treatment for toxin-mediated diseases. The development of hybridoma technology has allowed the isolation of monoclonal antibodies (mAbs) with high specificity and defined properties, and numerous mAbs have been purified and characterized for their protective efficacy against different toxins. This review summarizes the mAb studies for 6 toxins--Shiga toxin, pertussis toxin, anthrax toxin, ricin toxin, botulinum toxin, and Staphylococcal enterotoxin B (SEB)--and analyzes the prevalence of mAb functions and their isotypes. Here we show that most toxin-binding mAbs resulted from immunization are non-protective and that mAbs with potential therapeutic use are preferably characterized. Various common practices and caveats of protection studies are discussed, with the goal of providing insights for the design of future research on antibody-toxin interactions.

UR - http://www.scopus.com/inward/record.url?scp=84871700780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871700780&partnerID=8YFLogxK

M3 - Article

C2 - 22822456

AN - SCOPUS:84871700780

VL - 4

SP - 430

EP - 454

JO - Toxins

JF - Toxins

SN - 2072-6651

IS - 6

ER -